ADIPS Mini Oral Australasian Diabetes in Pregnancy Society and Society of Obstetric Medicine Australia and New Zealand Joint Scientific Meeting 2025

Improving HbA1c on 3rd trimester type 1 diabetes pregnancy with CamAPS FX: clinical outcomes and economic impact for the Australian healthcare system. (128047)

Helen R Murphy 1 , Aesha Khan Mirón 2 , Glynis Ross 3 4 , David Simmons 5 6 7 , Tara Lee 1 , Eleanor Scott 8 , Federi Carrieri 9 , Maria Eleni Syleouni 2
  1. University of East Anglia, Norwich, UK
  2. Ypsomed Diabetes Care AG, Burgdorf, SWITZERLAND, Switzerland
  3. Faculty of Medicine and Health, University of Sydney, NSW, Australia
  4. Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
  5. School of Medicine, Western Sydney University , Sydney, Australia
  6. Macarthur Diabetes Endocrinology and Metabolism Services, Campbelltown Hospital, Sydney, Australia
  7. Diabetes Australia, Sydney, Australia
  8. School of Medicine, University of Leeds, Leeds, UK
  9. Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), G. d’Annunzio University CHIETI-PESCARA, Chieti, Italy

Objective: Hyperglycaemia in pregnant women with type 1 diabetes (PWwT1D) increases the risk of obstetric and neonatal complications. This study aims to assess the clinical and economic impact of PWwT1D achieving tighter glycemic control with an Automated Insulin Delivery (AID) system (CamAPS FX) and compared to the standard of care (SoC).

Methods: A health economics decision tree model was developed based on AiDAPT study HbA1c distributions and related clinical outcomes. Obstetric outcomes included preeclampsia and birth method. Neonatal outcomes were assessed by length of stay (LOS) in normal, special, and intensive care units. A 0.3% adjusted mean difference in HbA1c, with associated AiDAPT RCT outcomes, were applied for the CamAPS FX group and Australian-specific healthcare costs were used to estimate economic impact.

Results: CamAPS FX use in AiDAPT resulted in improved health outcomes, reducing preeclampsia risk by 13% and increasing vaginal delivery rates. Neonatal LOS in special care decreased by 16%, and in intensive care by 12%. Overall, there was potential of AUD1,699  (95% Confidence Interval: -4,990- 8342) saved per PWwT1D treated with CamAPS FX vs standard of care. Cost savings were largely driven by reduced neonatal complications, accounting for 92% of total cost savings.

Conclusion: Despite the conservative analysis, including only perinatal costs, this analysis showcases both the clinical and economic advantages of the use of CamAPS FX over SoC in PWwT1D. Use of CamAPS FX is effective in optimizing blood glucose during pregnancy, both from a clinical and from an economic point of view.